[1]Li J N, Cui Z, Long J Y, et al. Primary glomerular nephropathy among hospitalized patients in a national database in China[J]. Nephrol Dial Transplant, 2018, 33(12): 2173-2181.
[2]Hou W Y, Shi S F, Yan Z, et al. Trends and the role of gene-environment interactions in idiopathic membranous nephropathy in northern China[J]. Am J Nephrol, 2025, 56(2): 148-157.
[3]Ronco P, Debiec H. Pathophysiological advances in membranous nephropathy: time for a shift in patients care[J]. Lancet, 2015, 385(9981): 1983-1992.
[4]Beck L H Jr, Bonegio R G, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy[J]. N Engl J Med, 2009, 361(1): 11-21.
[5]Huang C C, Lehman A, Albawardi A, et al. IgG subclass staining in renal biopsies with membranous glomerulonephritis indicates subclass switch during disease progression[J]. Mod Pathol, 2013, 26(6): 799-805.
[6]Dong H R, Wang Y Y, Cheng X H, et al. Retrospective study of phospholipase A2 receptor and IgG subclasses in glomerular deposits in Chinese patients with membranous nephropathy[J]. PLoS One, 2016, 11(5): e0156263.
[7]Hemminger J, Nadasdy G, Satoskar A, et al. IgG subclass staining in routine renal biopsy material[J]. Am J Surg Pathol, 2016, 40(5): 617-626.
[8]Seifert L, Zahner G, Meyer-Schwesinger C, et al. The classical pathway triggers pathogenic complement activation in membranous nephropathy[J]. Nat Commun, 2023, 14(1): 473.
[9]Kistler A D, Salant D J. Complement activation and effector pathways in membranous nephropathy[J]. Kidney Int, 2024, 105(3): 473-483.
[10]Segawa Y, Hisano S, Matsushita M, et al. IgG subclasses and complement pathway in segmental and global membranous nephropathy[J]. Pediatr Nephrol, 2010, 25(6): 1091-1099.
[11]Ueki K, Tsuchimoto A, Matsukuma Y, et al. Combined evaluation of glomerular phospholipase A2 receptor and immunoglobulin G subclass in membranous nephropathy[J]. Clin Kidney J, 2024, 17(6): sfae104.
[12]Na W, Yi K, Song Y S, et al. Dissecting the relationships of IgG subclasses and complements in membranous lupus nephritis and idiopathic membranous nephropathy[J]. PLoS One, 2017, 12(3): e0174501.
[13]Sethi S, Fervenza F C. Antigens in membranous nephropathy: discovery and clinical implications[J]. Nat Rev Nephrol, 2025, 21(10): 653-670.
[14]Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions[J]. Front Immunol, 2014, 5: 520.
[15]Cui H Y, Li C, Li H, et al. Analysis of glomerular IgG subclasses switch in idiopathic membranous nephropathy classified by glomerular phospholipase A2 receptor antigen and serum antibody[J]. Dis Markers, 2021, 2021: 9965343.
[16]Zhong Y Z, Liu Y Y, Zhou D, et al. Serum PLA2R-IgG4/PLA2R-IgG ratio dynamics reveal pathogenic autoantibody subclass switch during progression of PLA2R-associated membranous nephropathy[J]. Ann Med, 2026, 58(1): 2610874.
[17]Hofstra J M, Debiec H, Short C D, et al. Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy[J]. J Am Soc Nephrol, 2012, 23(10): 1735-1743.
[18]Haddad G, Lorenzen J M, Ma H, et al. Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1-associated membranous nephropathy[J]. J Clin Invest, 2021, 131(5): e140453.
[19]Yang Y, Wang C, Jin L P, et al. IgG4 anti-phospholipase A2 receptor might activate lectin and alternative complement pathway meanwhile in idiopathic membranous nephropathy: an inspiration from a cross-sectional study[J]. Immunol Res, 2016, 64(4): 919-930.
[20]Sethi S, Fervenza F C. Membranous nephropathy-diagnosis and identification of target antigens[J]. Nephrol Dial Transplant, 2024, 39(4): 600-606.
[21]Zhang J L, Fan Z J, Wang P X, et al. Phospholipase A2 receptor antibodies and clinical prognosis in patients with idiopathic membranous nephropathy: an updated systematic review and meta-analysis[J]. Kidney Blood Press Res, 2023, 48(1): 102-113.
|